Cystic Fibrosis Year in Review 2023

Overview

Journal Pediatr Pulmonol

Specialties Pediatrics
Pulmonary Medicine

Date 2024 Jul 26

PMID 39056532

Authors

David V Swetland

Adrienne P Savant

Affiliations

Soon will be listed here.

Abstract

This past year, there were many important advances for patients with cystic fibrosis (CF). Of the many publications related to CF in 2023, there was further evaluation of highly effective modulator therapy, new assessments and guidelines for clinical manifestations and therapies for CF, advances in newborn screening and diagnosis, and evaluation of outcomes for people with CF transmembrane conductance regulator-related metabolic syndrome/CF screen positive, inconclusive diagnosis. The aim of this review article is not to provide a full assessment of the wide range of articles published in 2023, but to provide a brief review of publication that may lead to changes in clinical care.

Citing Articles

Same-Day Repeatability and 28-Day Reproducibility of Xenon MRI Ventilation in Children With Cystic Fibrosis in a Multi-Site Trial.

Walkup L, Roach D, Plummer J, Willmering M, Zanette B, Santyr G J Magn Reson Imaging. 2024; 61(4):1664-1674.

PMID: 39257323 PMC: 11896927. DOI: 10.1002/jmri.29605.

Cystic fibrosis year in review 2023.

Swetland D, Savant A Pediatr Pulmonol. 2024; 59(12):3106-3116.

PMID: 39056532 PMC: 11601032. DOI: 10.1002/ppul.27190.

References

Andrejak C, Priou P, Richaud-Thiriez B, Macey J, Montcouquiol S, Douvry B . The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del variant. Eur Respir J. 2023; 61(5. DOI: 10.1183/13993003.02437-2022. View

Beck M, Hornick D, Pena T, Singh S, Wright B . Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis. Pediatr Pulmonol. 2023; 58(5):1569-1573. DOI: 10.1002/ppul.26362. View

Lebecque P, Thimmesch M, Meurrens J, Jeanmart P . Cystic fibrosis: Does it matter to avoid crushing Elexacaftor/Tezacaftor/Ivacaftor (ETI) tablets?. Pediatr Pulmonol. 2023; 58(12):3603-3604. DOI: 10.1002/ppul.26682. View

Blanchard A, Shaw M, Ratjen F, Tullis E, Daneman N, Waters V . Factors associated with lung function response with oral antibiotic treatment of pulmonary exacerbations in cystic fibrosis. J Cyst Fibros. 2023; 22(5):880-883. DOI: 10.1016/j.jcf.2023.06.015. View

Sears Jr E, Hinton A, Lopez-Pintado S, Lary C, Zuckerman J . Gaps in Cystic Fibrosis Care Are Associated with Reduced Lung Function in the U.S. Cystic Fibrosis Foundation Patient Registry. Ann Am Thorac Soc. 2023; 20(9):1250-1257. DOI: 10.1513/AnnalsATS.202211-951OC. View

Chiuve S, Fife D, Leitz G, Peterson C, Campbell N, Rennig A . Incidence of fibrosing colonopathy with pancreatic enzyme replacement therapy in patients with cystic fibrosis. J Cyst Fibros. 2023; 22(6):1017-1023. DOI: 10.1016/j.jcf.2023.08.013. View

Goralski J, Hoppe J, Mall M, McColley S, McKone E, Ramsey B . Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One Allele. Am J Respir Crit Care Med. 2023; 208(1):59-67. PMC: 10870849. DOI: 10.1164/rccm.202301-0084OC. View

Casaredi I, Shaw M, Waters V, Seeto R, Blanchard A, Ratjen F . Impact of antibiotic eradication therapy of Pseudomonas aeruginosa on long term lung function in cystic fibrosis. J Cyst Fibros. 2022; 22(1):98-102. DOI: 10.1016/j.jcf.2022.08.007. View

Drummond D, Whelan P, Sperrin M . Association between nebuliser therapies adherence and visit-to-visit variability of FEV1 in patients with cystic fibrosis. J Cyst Fibros. 2023; 22(4):702-705. DOI: 10.1016/j.jcf.2023.03.006. View

10.

Leung D, Ye W, Schwarzenberg S, Freeman A, Palermo J, Weymann A . Long-term follow-up and liver outcomes in children with cystic fibrosis and nodular liver on ultrasound in a multi-center study. J Cyst Fibros. 2022; 22(2):248-255. DOI: 10.1016/j.jcf.2022.07.017. View

11.

Thornton C, Magaret A, Carmody L, Kalikin L, Simon R, LiPuma J . Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes. J Cyst Fibros. 2023; 23(2):321-328. PMC: 10674030. DOI: 10.1016/j.jcf.2023.05.011. View

12.

McGarry M, Huang C, Ly N . Ethnic differences in staphylococcus aureus acquisition in cystic fibrosis. J Cyst Fibros. 2023; 22(5):909-915. PMC: 10802839. DOI: 10.1016/j.jcf.2023.07.004. View

13.

Casey M, Gabillard-Lefort C, McElvaney O, McElvaney O, Carroll T, Heeney R . Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax. 2023; 78(8):835-839. DOI: 10.1136/thorax-2022-219943. View

14.

Patel P, Yeley J, Brown C, Wesson M, Lesko B, Slaven J . Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor. Int J Neonatal Screen. 2023; 9(1). PMC: 10056483. DOI: 10.3390/ijns9010010. View

15.

Berlinski A, Leisenring P, Willis L, King S . Home Spirometry in Children with Cystic Fibrosis. Bioengineering (Basel). 2023; 10(2). PMC: 9952128. DOI: 10.3390/bioengineering10020242. View

16.

Hjelm M, Hente E, Miller J, Moore S, Peugh J, Swetland D . Longitudinal mental health trends in cystic fibrosis. J Cyst Fibros. 2023; 22(6):1093-1099. DOI: 10.1016/j.jcf.2023.06.009. View

17.

Yanaz M, Yilmaz Yegit C, Gulieva A, Kalyoncu M, Selcuk M, Uzunoglu B . Electronic home monitoring of children with cystic fibrosis to detect and treat acute pulmonary exacerbations and its effect on 1-year FEV. J Cyst Fibros. 2023; 23(2):329-333. DOI: 10.1016/j.jcf.2023.09.007. View

18.

McElvaney O, Heltshe S, Odem-Davis K, West N, Sanders D, Fogarty B . Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis. Ann Am Thorac Soc. 2023; 21(5):716-726. PMC: 11109904. DOI: 10.1513/AnnalsATS.202308-673OC. View

19.

Shum B, Sng L, Ruseckaite R, Henner I, Twine N, Bauer D . The inequity of targeted cystic fibrosis reproductive carrier screening tests in Australia. Prenat Diagn. 2022; 43(1):109-116. DOI: 10.1002/pd.6285. View

20.

Filipow N, Stanojevic S, Raywood E, Shannon H, Tanriver G, Kapoor K . Real-world effectiveness of airway clearance techniques in children with cystic fibrosis. Eur Respir J. 2023; 62(3). PMC: 10492663. DOI: 10.1183/13993003.00522-2023. View